Kathleen Heffernan..... Vincent Gotz..... Corporate....

Vincent Gotz

Summary
  • Twelve (12) years of clinical pharmacy practice and research experiences in large university hospital settings
  • Eighteen (18) years experience in public and private pharmaceutical and biomedical companies in various management capacities (R&D, Strategic Planning and Licensing/Business Development, Sales/Marketing)
  • Industry experience includes twelve (12) years in business development/licensing activities including eight (8) years of assessing and partnering of drug delivery technologies.

Areas of Expertise

  • Product and technology partnering
  • Strategy development and implementation
  • Market assessment and analysis
  • Technology assessment and due diligence
  • Broad based understanding of pharmaceutical research and development
  • Excellent communication and public speaking skills
  • International experience (Europe and Japan) in working with management, clinicians and pharmaceutical scientists

Education

1992

 M.B.A. (with distinction)
Keller Graduate School of Management
Kansas City, Missouri

1974

 M.S. in Clinical Pharmacy (with high honors)
Purdue University
West Lafayette, Indiana

1973

 Residency Certificate
Hospital Pharmacy Residency
St. Mary’s Hospital, Mayo Clinic
Rochester, Minnesota

1972

 B.S. in Pharmacy (with honors)
University of Wisconsin
Madison, Wisconsin

Professional Experience

2005

   Managing Partner, ProPharmaCon LLC, San Diego, California

2003

   Senior Vice President, Business Solutions, ProSanos Corporation, La Jolla, California

2002

   Chief Business Officer, GeneFormatics, Inc, San Diego, California.

2001

   Vice President, Business Development, Epicyte Pharmaceutical, Inc, San Diego, California.

1996

  Senior Director, Business Development and Planning, Dura Pharmaceuticals, Inc, San Diego, California.

1993

  Director, Business Development, Dura Pharmaceuticals, Inc, San Diego, California.

1993

   Senior Manager, Product Assessment and Scientific Liaison, Asian Licensing, Marion Merrell Dow Inc, Kansas City, Missouri.

1990

  Manager, Product Assessment and Scientific Liaison, Asian Licensing, Marion Merrell Dow Inc, Kansas City, Missouri.

1987

  Senior Drug Evaluation Scientist, Marion Laboratories, Kansas City, Missouri.

1985

  Associate Chairman, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida.

1982

   Associate Professor (tenured), Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida.

1980

   Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida.

1978

  Instructor in Pharmacology, Cornell University Medical College, New York, New York.

1977

  Assistant Director of Comprehensive Pharmaceutical Services, The New York Hospital-Cornell Medical Center, New York, New York.

1975

  Clinical Coordinator of Pharmacy Services, Medicine, The New York Hospital-Cornell Medical Center, New York, New York.

1974

  Assistant Director, Department of Pharmaceutical Services, Shands Teaching Hospital, University of Florida, Gainesville, Florida.
Publications - Refereed
    1. Gotz VP. Penicillin Desensitization - A Case Review. Drug Intell Clin Pharm 1976; 10:333-7.
    2. Romankiewicz JA, Gotz VP, Carlin HS. Development of Patient Medication Instruction Cards. Am J Hosp Pharm 1976; 33:928-31.
    3. Gotz VP, Lauper RD. Beclomethasone Dipropionate. Drug Intell Clin Pharm 1976;10:635-7.
    4. Romankiewicz JA, Gotz VP, Capelli A, Carlin HS. An Interdisciplinary Approach to Improved Patient Compliance. Am J Nurs 1978;78:1216-9.
    5. Gotz B, Gotz VP. Drugs and the Elderly. Am J Nurs 1978;78:1347-51.
    6. Gotz VP. Corticosteroid Aerosol Therapy in Asthma. US Pharmacist 1978;3:74-82.
    7. Romankiewicz JA, Gotz VP, Carlin HS. Patient Medication Instruction Cards: Effect on Patient Drug Knowledge. US Pharmacist 1978;3:H-24-H-34.
    8. Gotz VP, Romankiewicz JA, Moss J, Murray H. Prophylaxis Against Ampicillin-Associated Diarrhea with a Lactobacillus Preparation. Am J Hosp Pharm 1979;
      36:754-7.
    9. Gotz VP, Drayer D, Schned E, Reidenberg M. An Unusual Cause of Theophylline Toxicity. NY State J Med 1979;79:1232-4.
    10. Gotz VP. Jones BR. Complications of Cancer Chemotherapy. US Pharmacist 1979;4:H-1-H-24.
    11. Romankiewicz JA, McManus J, Gotz VP, Carlin HS. Medications Not to be Refrigerated. Am J Hosp Pharm 1979;36:1541-5.
    12. Brause BD, Romankiewicz JA, Gotz VP, Franklin JE, Roberts RB. Comparative Study of Diarrhea Associated with Clindamycin and Ampicillin Therapy. Am J Gastroenterol 1980;73:244-8.
    13. Brandstetter RD, Gotz VP, Mar DD. Optimal Dosing of Epinephrine in Acute Asthma. Am J Hosp Pharm 1980;37:1326-9.
    14. Gotz VP, Mar DD, Roche JJ. Compatibility of Amphotericin B with Drugs Used to Reduce Adverse Reactions. Am J Hosp Pharm 1981;38:378-9.
    15. Brandstetter RD, Gotz VP, Mar DD. Identifying the Acutely Ill Patient with Asthma. South Med J 1981;74:713-5.
    16. Gotz VP, Ryerson GG. Medical Management of Status Asthmaticus in Adults. US Pharmacist 1981;6:H-2-H-24.
    17. Brandstetter RD, Gotz VP, Mar DD, Sachs D. Exacerbation of Diazepam-Induced Phlebitis by Oral Penicillamine. Br Med J 1981;283:525.
    18. Gotz VP, Brandstetter RD, Mar DD. Bronchodilatory Effects of Subcutaneous Epinephrine in Acute Asthma. Ann Emerg Med 1981;10:518-20.
    19. Wasserman FE, Gotz VP. Outpatient Prescribing and Monitoring of a Sustained-Release Theophylline Preparation. Hosp Pharm 1981;16:542-5.
    20. Iafrate RP, Gotz VP, Robinson JD, Lupkiewicz SM. Computer-Simulated Conversion from Intravenous to Sustained-Release Oral Theophylline. Drug Intell Clin Pharm 1982;16:19-25.
    21. Gotz VP, Rand KH. Medical Management of Antimicrobial-Associated Diarrhea and Colitis. Pharmacotherapy 1982;2:100-9.
    22. Gordon SR, Gotz VP, Yost RL, Ryerson GG. Comparative Effects of Metoprolol and Propranolol on Pulmonary Function. Curr Ther Res 1982;31:346-53.
    23. Gotz VP, Lopez LM, Reeves SE, Morrow ME. Clinical Utilization of Serum Theophylline Concentrations in a University-Affiliated Hospital. Drug Intell Clin Pharm 1982;16:872-4.
    24. Gotz VP, Russell WL, Lopez LM. Evaluation of the Condition Correction Factor Method of Estimating Theophylline Clearance. Ther Drug Monit 1983;5:103-7.
    25. Massey KL, Gotz VP. Anticholinergic Therapy of Chronic Obstructive Pulmonary Diseases. Fla J Hosp Pharm 1983;3:65-9.
    26. Gotz VP, Dolly FR, Block AJ. Influence of Medroxyprogesterone on Theophylline Disposition. J Clin Pharmacol 1983;23:281-4.
    27. Hatton RC, Gotz VP, Robinson JD, Russell WL, Ryerson GG. Conversion from Intravenous Aminophylline to Sustained-Release Theophylline: Computer Simulation versus In Vivo Results. Clin Pharm 1983;2:347-52.
    28. Iafrate RP, Yost RL, Curry SH, Gotz VP, Caranasos GJ. Effect of Dose and Ointment Application Technique on Nitroglycerin Plasma Concentrations. Pharmacotherapy 1983;3:118-24.
    29. Gotz VP, Yost RL, Lamadrid ME, Buchanan CD. Evaluation of a Potential Interaction: Thioridazine-Phenytoin. Hosp Pharm 1984;19:555-7.
    30. Massey KL, Gotz VP, Russell WL. Dose-Dependent Kinetics of Theophylline in Adults with Pulmonary Diseases. Ther Drug Monit 1984;6:284-9.
    31. Massey KL, Gotz VP. New Drug Evaluation: Ipratropium Bromide. Drug Intell Clin Pharm 1985;19:5-12.
    32. Gotz VP, Rand KH, Kramer BS. Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse Reactions. Drug Intell Clin Pharm 1985;19:436-9.
    33. Parish RC, Moore RT, Gotz VP. Seizures Following Oral Lidocaine for Esophageal Anesthesia. Drug Intell Clin Pharm 1985;19:199-201.
    34. Price W, Coli L, Brandstetter RD, Gotz VP. Ranitidine-Associated Hallucinations. Eur J Clin Pharmacol 1985;29:375-6.
    35. Yost RL, Gotz VP. Effect of a Lactobacillus Preparation on the Absorption of Oral Ampicillin. Antimicrob Agent Chemother 1985;28:727-9.
    36. Gotz VP, Ryerson GG. Evaluation of Tetracycline on Theophylline Disposition in Patients with Chronic Obstructive Airways Disease. Drug Intell Clin Pharm 1986;20:694-7.
    37. Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L. Evaluation of the Asthmogenicity of Propafenone, a New Antiarrhythmic. Chest 1986;90:698-702.
    38. Mullersman G, Gotz VP, Russell WL, Derendorf H. Lack of Clinically Significant In Vitro and In Vivo Interactions Between Ranitidine and Sucralfate. J Pharm Sci 1986;75:995-8.
    39. Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum Lidocaine Concentrations Following Application to the Oropharynx: Effect of Cimetidine. Ther Drug Monit 1987;9:292-7.
    40. Gotz VP. Drug Interactions with Oral Antimicrobial Therapy: A Need for Consideration. Resident Staff Phys 1987;33:45-60.
    41. Smith PD, Gotz VP, Ryerson GG. Investigational Drug Evaluation: Almitrine Bismesylate. Drug Intell Clin Pharm 1987;21:417-21.
    42. Parish RC, Gotz VP, Mehta JL. Cimetidine Does Not Increase Alpha-1 Acid Glycoprotein Serum Concentration. Br J Clin Pharmacol 1988;25:514-7.
    43. Hooshmand-Rad R, Chu A, Gotz V, Morris J, Batty S, Freifeld A. Use of Amphotericin B Lipid Complex in Elderly Patients. J Infection 2005;50:277-87.
    44. Meier-Kriesche H-U, Morris JA, Chu AH, Steffen BJ, Gotz VP, Gordon RD, Kaplan B. Mycophenolate Mofetil versus Azathioprine in a Large Population of Elderly Renal Transplant Patients. Neph Dial Transplant 2004;19:2864-9.
    45. Hooshmand-Rad R, Reed MD, Chu A, Gotz V, Morris JA, Weinberg J, Dominguez EA. Retrospective Study of the Renal Effects of Amphotericin B Lipid Complex When Used at Higher-Than-Recommended Dosages and Longer Durations Compared with Lower Dosages and Shorter Durations in Patients with Systemic Fungal Infections. Clin Ther 2004;26:1652-62.
    46. Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, Gordon RD. Daclizumab is Associated with Decreased Rejection and Improved Patient Survival in Renal Transplant Recipients. Clin Transplant 2005; 19:340-45
 

Download Resume